CMS Should Verify Part B Drug Pricing From Manufacturers, GAO Says
Executive Summary
CMS 'concurs' with GAO’s recommendation on ASP reports but it’s unclear how much more aggressively it will pursue underlying documentation.
You may also be interested in...
CMS Should Fully Automate ASP Data Submissions, OIG Says
Manufacturers’ submissions of average sales price data from drugs are entered manually by CMS staff; the HHS Inspector General recommends a fully automated process like the one used for average manufacturer price submissions.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.